# ASPirin in Reducing Events in the Elderly - eXTension

> **NIH NIH U19** · HENNEPIN HEALTHCARE RESEARCH INSTITUTE · 2021 · $340,492

## Abstract

PROJECT SUMMARY / ABSTRACT
Genomics has become an increasingly important aspect of large clinical trials and cohort studies. Genomic data is
an essential component for investigating of the joint contribution of environmental and inherited factors on health
and disease during ageing. However, the value of genomic information can rarely be achieved by the analysis of
data from a single cohort. Rather, data from multiple cohorts must be combined together into a consortium, to
achieve statistical power required for novel gene discovery. Many of prominent genomics consortia involve
contribution of genomic data from many different NIH-funded cohorts, for genome-wide association studies
(GWAS) and meta-analyses. Examples include the Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) consortium, the Alzheimer's Disease Genetics Consortium (ADGC), and the Alzheimer's
Disease Sequencing Project (ADSP). Our study, the ASPirin in Reducing Events in the Elderly (ASPREE) trial -
and subsequent observational extension study (ASPREE-XT) - have been fortunate to have collected
biospecimens via the ASPREE Healthy Ageing Biobank and generated genomic data on a majority of participants
(~15,000 healthy older individuals with targeted sequencing and genome-wide SNP data). This information is of
now significant value to in the work of our U19 AG062682 in determining the relative and joint impact of lifestyle,
genomics and environmental influences on health in an older population. The availability of the genomic datasets
also has presented recent opportunities and imperatives for ASPREE-XT to enter genomics consortia, to contribute
to gene discovery efforts. The large size and high quality of ASPREE-XT data will make the study a particularly
important (& often dominant) component of these consortia. Yet the current resources within ASPREE-XT to
participate in a leadership role in these collaborative ventures is limited. Given the significance of the ASPREE-XT
contribution, it requires ASPREE-XT investigators taking leadership roles in these consortia – including in the
analysis of consortia data and leading publications. Making this type of contribution is proving increasingly complex
and time consuming, given the ongoing efforts required in each consortium to attend working groups, contribute
intellectually, participate in analyses, papers etc. In this administrative supplement, we are requesting supplemental
funding to enable ASPREE-XT investigators to participate fully in these genomics consortia, with a focus on those
related to Alzheimer's Dementia, and contribute to scientific outputs. This would improve the exposure and profile
of the ASPREE-XT study, and elevate the overall impact and prominence of the ASPREE-XT research program,
especially in the area of dementia and Alzheimer's disease genetics, where considerable opportunities exist for
ASPREE-XT to make meaningful contributions. The consortia opportunities have mostly emerged only recentl...

## Key facts

- **NIH application ID:** 10416528
- **Project number:** 3U19AG062682-03S1
- **Recipient organization:** HENNEPIN HEALTHCARE RESEARCH INSTITUTE
- **Principal Investigator:** Andrew T Chan
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $340,492
- **Award type:** 3
- **Project period:** 2019-07-15 → 2024-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10416528

## Citation

> US National Institutes of Health, RePORTER application 10416528, ASPirin in Reducing Events in the Elderly - eXTension (3U19AG062682-03S1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10416528. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*